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OBJECTIVE: Bisphosphonates inhibit bone resorption, reducing
skeletal-related events (SREs) and bone pain in breast cancer
patients with bone metastasis. These agents are characterized by
different efﬁcacy, safety, dosage form, time of administration,
compliance, and acquisition costs. We developed formal budget
impact model to guide the selection of bisphosphonate therapy
from the perspective of the UK NHS. METHODS: We developed
a Markov model to simulate over a period of seven years the the
incidence of SREs and cost of care for a hypothetical cohort of
1000 patients receiving no treatment (NT), daily oral iban-
dronate (OI), or monthly injections of generic pamidronate 
(PA) or zoledronic acid (ZA). This literature-based model
included assumptions about skeletal morbidity rates (SMR,
directly obtained or extrapolated from placebo-controlled clini-
cal trials), mortality, costs of drug (including infusion cost), cost
of SRE, and compliance with therapy. Survival was assumed to
be identical across all groups (25 months). RESULTS: Based on
relative reductions of risk of SREs (ratio of SMR of bisphos-
phonate therapy vs. no therapy) and compliance with therapy,
the cumulative number of SREs over the lifetime of a patient 
was projected to be lowest for ZA (3820 events), followed by
PA (4430), OI (4910), and NT (6020). Total discounted costs
(including drug, infusion administration costs, SRE treatment
costs) for the cohorts of 1000 patients were £1,949,000 lower
for ZA than OI, £1,160,000 lower than PA, and £556,000 
lower than NT. Fifty and 75% of these savings, respectively,
occurred within the ﬁrst 12 and 24 months of the simulation.
These ﬁndings were robust across various sensitivity analyses.
CONCLUSIONS: For breast cancer patients with bone metas-
tasis, zoledronic acid appears to be the most cost-effective 
and least costly bisphosphonate therapy, even compared to no
therapy.
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OBJECTIVE: To determine the long term beneﬁts and costs of
primary (tamoxifen) and secondary (mammography) breast
cancer preventive strategies in healthy women who are at high
risk of developing breast cancer. METHODS: A Markov process
with time and state dependent transition probabilities was 
developed. Three hypothetical cohorts of high risk women 
were initiated at age 40 and were simulated over their lifetime.
Cohort one consumed tamoxifen and underwent routine mam-
mography screening. Cohort two consumed tamoxifen but
underwent mammography screening at rates observed in clinical
practice (sub-optimal compliance) and Cohort three, which
served as the control, did not consume tamoxifen and underwent
mammography screening at rates observed in clinical practice
(sub-optimal). Chemopreventive tamoxifen effect was modeled
based on the ﬁve-year Breast Cancer Prevention Trial results
while mammography efﬁcacy data was based on data from 
published analysis which investigated effect of mammography
screening on mortality. All cause and disease speciﬁc mortality
rates were based on data calculated from life tables and 
other published sources. All costs and efﬁcacy were determined
using 3% discount rate. RESULTS: Tamoxifen coupled with
routine mammography screening resulted in an incremental life
expectancy gain of 0.122 years at an incremental cost of 
$5969.7 resulting in an ICER of $48,931.8/life year gained com-
pared to control group. Tamoxifen coupled with mammography
screening at rates observed in clinical practice resulted in an
ICER of $64,695.2/life year gained. Sensitivity analysis involv-
ing varying intervention effectiveness, adverse events resulting
from tamoxifen, intervention compliance, and mortality rates
associated with different health states, revealed the robustness 
of results over a wide range of assumptions. CONCLUSIONS:
Chemopreventive tamoxifen coupled with routine mammo-
graphy screening in women who are healthy but at high 
risk for developing breast cancer was found to be a cost-
effective strategy. The results were robust over a wide range of
assumptions.
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OBJECTIVES: Capecitabine (Xeloda®), an oral chemothera-
peutic agent, is effective to treat both adjuvant and metastatic
colorectal cancer (CRC) patients. In the recent X-ACT trial,
capecitabine compared with intravenous 5-FU/LV adjuvant
therapy demonstrated superior relapse-free survival (65.5% vs.
61.9% at three years follow-up (p = 0.0407) in patients with
Dukes’ C colon cancer and improved covariate-adjusted overall
survival (p = 0.0208). Based on results from X-ACT, this study
assesses the cost-effectiveness of capecitabine from both US
payer and societal perspectives. METHODS: Trial-based data
were collected on treatment period medical resource use. Unit
costs for drug administration, hospitalizations, consultations,
concomitant medications, and patient time were imputed using
published sources. A health-state transition model was used to
estimate incremental cost impact and effectiveness in terms of
the gains in relapse-free months (RFMs) (mean trial follow-up:
3.8 years) and life years (LYs). Future outcomes were discounted
at 3% annually. RESULTS: Mean duration of treatment was
approximately 24 weeks in both arms. Administration of
capecitabine required fewer clinic visits per patient (7.4 vs. 28.0
with 5-FU/LV). Mean acquisition costs of capecitabine were
$8700 higher than with 5-FU/LV, but these costs were partially
offset by 5-FU/LV’s administration cost of $5700. Total hospital
days for treatment-related adverse events (AEs), medication costs
for treating AEs, and patient time costs were higher for 5-FU/LV.
The cost of physician consultations for treating AEs did not
differ. Compared to 5-FU/LV, capecitabine increases RFMs by
1.3 months at four years yielding a cost-effectiveness ratio of
$2500 per RFM gained (payer perspective); from a societal, life-
time perspective, capecitabine increases LYs by 11.3 months with
a cost per LY gained of $500. This ﬁnding was not sensitive to
plausible variations in key parameters. CONCLUSIONS: Based
on our model, capecitabine, an oral chemotherapeutic agent, is
cost-effective in the US compared with intravenous 5-FU/LV in
treating patients with adjuvant CRC.
